12 April, 2019

Maymó launches TILKOMAY, an innovative association for the treatment of BRD

Tilkomay is an injectable association of tilmicosin and ketoprofen for the treatment of BRD associated with pyrexia. Tilkomay is administrated through subcutaneous route.

On one hand, tilmicosin has a high affinity for lung tissue. The high and long-lasting concentration in lung is responsible for its efficacy. On the other hand, this is the first time that a ketoprofen product is authorized for subcutaneous administration. Tilkomay has demonstrated that this new route of administration strengthens the antipyretic effect of ketoprofen, allowing a better recovery of the animals.

Tilkomay is administered on a single occasion only: 1 ml of Tilkomay/30 kg bw. Tilkomay is available in polypropylene vials of 100 ml and 250 ml.